Keigo Hara
Papers
1
Total Citations
13
H-Index
1
About
Keigo Hara is a clinical researcher whose work centers on the safety and real-world application of novel therapies for advanced gastric cancer. His most-cited study, a 2025 case series on zolbetuximab, documents two instances of protein-losing enteropathy—a rare but serious adverse event—in patients with CLDN18.2-positive, HER2-negative unresectable disease. This contribution is critical because, while the landmark GLOW and SPOTLIGHT trials established zolbetuximab’s efficacy, Hara’s work provides the first detailed clinical evidence of this complication outside a trial setting, alerting oncologists to a potentially underrecognized toxicity. With 13 citations in a short time, his paper has already shaped safety monitoring protocols. Hara’s focus on bridging the gap between controlled trials and real-world practice underscores his commitment to improving patient outcomes. His findings serve as a vital cautionary note for clinicians adopting this targeted therapy, highlighting the importance of vigilance for gastrointestinal adverse events.
Research Focus
Key Achievements
Top Papers
- 1